References

1. WHO, “Obesity: preventing and managing the global epidemic: report of WHO consultation,” Tech. Rep. 884, WHO Consultation on Obesity, Geneva, Switzerland, 1999.

   View at: Google Scholar

2. S. Nammi, S. Koka, K. M. Chinnala, and K. M. Boini, “Obesity: an overview on its current perspectives and treatment options,” Nutrition Journal, vol. 3, p. 3, 2004.

   View at: Publisher Site | Google Scholar

3. A. von Eckardstein and G. Assmann, “Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?,” Current Opinion in Lipidology, vol. 11, no. 6, pp. 627–637, 2000.

   View at: Publisher Site | Google Scholar

4. P. T. James, N. Rigby, and R. Leach, “The obesity epidemic, metabolic syndrome and future prevention strategies,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 11, no. 1, pp. 3–8, 2004.

   View at: Publisher Site | Google Scholar

5. E. N. Liberopoulos, D. P. Mikhailidis, and M. S. Elisaf, “Diagnosis and management of the metabolic syndrome in obesity,” Obesity Reviews, vol. 6, no. 4, pp. 283–296, 2005.

   View at: Publisher Site | Google Scholar

6. J. Korner and L. J. Aronne, “Pharmacological approaches to weight reduction: therapeutic targets,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2616–2621, 2004.

   View at: Publisher Site | Google Scholar

7. D. Cota and S. C. Woods, “The role of the endocannabinoid system in the regulation of energy homeostasis,” Current Opinion in Endocrinology and Diabetes, vol. 12, no. 5, pp. 338–351, 2005.

   View at: Publisher Site | Google Scholar

8. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004.

   View at: Publisher Site | Google Scholar

9. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000.

   View at: Publisher Site | Google Scholar

10. H. E. Xu, M. H. Lambert, and V. G. Montana et al., “Molecular recognition of fatty acids by peroxisome proliferator-activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999.

    View at: Publisher Site | Google Scholar

11. M. Guerre-Millo, P. Gervois, and E. Raspé et al., “Peroxisome proliferator-activated receptor $\alpha$ activators improve insulin sensitivity and reduce adiposity,” Journal of Biological Chemistry, vol. 275, no. 22, pp. 16638–16642, 2000.

    View at: Publisher Site | Google Scholar

12. E. Erol, L. S. Kumar, G. W. Cline, G. I. Shulman, D. P. Kelly, and B. Binas, “Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPAR$\alpha$ in fasting mice,” The FASEB Journal, vol. 18, no. 2, pp. 347–349, 2004.

    View at: Google Scholar

13. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-$\alpha$, -$\beta$, and -$\gamma$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.

    View at: Publisher Site | Google Scholar

14. W. R. Oliver, J. L. Shenk, and M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor $\delta$ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001.

    View at: Publisher Site | Google Scholar

15. Y.-X. Wang, C.-H. Lee, and S. Tiep et al., “Peroxisome-proliferator-activated receptor $\delta$ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.

    View at: Publisher Site | Google Scholar

16. Y. X. Wang, C. L. Zhang, and R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPAR$\delta$,” PLoS Biology, vol. 2, no. 10, p. e294, 2004.

    View at: Publisher Site | Google Scholar

17. B. M. Spiegelman, “PPAR-$\gamma$: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998.

    View at: Publisher Site | Google Scholar

18. L. Fajas, J.-C. Fruchart, and J. Auwerx, “Transcriptional control of adipogenesis,” Current Opinion in Cell Biology, vol. 10, no. 2, pp. 165–173, 1998.

    View at: Publisher Site | Google Scholar

19. M. Lehrke and M. A. Lazar, “The many faces of PPAR$\gamma$,” Cell, vol. 123, no. 6, pp. 993–999, 2005.

    View at: Publisher Site | Google Scholar

20. J. E. Cecil, P. Watt, C. N. Palmer, and M. Hetherington, “Energy balance and food intake: the role of PPAR$\gamma$ gene polymorphisms,” Physiology and Behavior, vol. 88, no. 3, pp. 227–233, 2006.

    View at: Publisher Site | Google Scholar

21. S. Mudaliar, A. R. Chang, and R. R. Henry, “Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications,” Endocrine Practice, vol. 9, no. 5, pp. 406–416, 2003.

    View at: Google Scholar

22. Y. Guan, C. Hao, and D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPAR$\gamma$ stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005.

    View at: Publisher Site | Google Scholar

23. M. C. Lewis, J. G. Wilson, D. M. Ignar, and W. R. Oliver, “The effects of PPAR$\alpha$, $\delta$ and PPARpan agonist on diet-induced obesity in fat-fed AKR mice,” Diabetes, vol. 53, supplement 2, p. A134, 2004.

    View at: Google Scholar

24. B. Pourcet, J.-C. Fruchart, B. Staels, and C. Glineur, “Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis,” Expert Opinion on Emerging Drugs, vol. 11, no. 3, pp. 379–401, 2006.

    View at: Publisher Site | Google Scholar

25. U. Ramachandran, R. Kumar, and A. Mittal, “Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome,” Mini-Reviews in Medicinal Chemistry, vol. 6, no. 5, pp. 563–573, 2006.

    View at: Publisher Site | Google Scholar

26. P. J. Brown, D. A. Winegar, and K. D. Plunket et al., “A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR$\alpha$ agonist with potent lipid-lowering activity,” Journal of Medicinal Chemistry, vol. 42, no. 19, pp. 3785–3788, 1999.

    View at: Publisher Site | Google Scholar

27. B. Yang, K. K. Brown, and L. Chen et al., “Serum adiponectin as a biomarker for in vivo PPAR$\gamma$ activation and PPAR$\gamma$ agonist-induced efficacy on insulin sensitization/lipid lowering in rats,” BMC Pharmacology, vol. 4, no. 1, p. 23, 2004.

    View at: Publisher Site | Google Scholar

28. B. R. Henke, S. G. Blanchard, and M. F. Brackeen et al., “$N$-(2-benzoylphenyl)-L-tyrosine PPAR$\gamma$ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents,” Journal of Medicinal Chemistry, vol. 41, no. 25, pp. 5020–5036, 1998.

    View at: Publisher Site | Google Scholar

29. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.

    View at: Publisher Site | Google Scholar

30. J. S. Nichols, D. J. Parks, T. G. Consler, and S. G. Blanchard, “Development of a scintillation proximity assay for peroxisome proliferator-activated receptor $\gamma$ ligand binding domain,” Analytical Biochemistry, vol. 257, no. 2, pp. 112–119, 1998.

    View at: Publisher Site | Google Scholar

31. G. L. Dohm, R. L. Huston, E. W. Askew, and P. C. Weiser, “Effects of exercise on activity of heart and muscle mitochondria,” The American Journal of Physiology, vol. 223, no. 4, pp. 783–787, 1972.

    View at: Google Scholar

32. H. R. Scholte, Y. Yu, J. D. Ross, I. I. Oosterkamp, A. M. C. Boonman, and H. F. M. Busch, “Rapid isolation of muscle and heart mitochondria, the lability of oxidative phosphorylation and attempts to stabilize the process in vitro by taurine, carnitine and other compounds,” Molecular and Cellular Biochemistry, vol. 174, no. 1-2, pp. 61–66, 1997.

    View at: Publisher Site | Google Scholar

33. D. M. Muoio, P. S. MacLean, and D. B. Lang et al., “Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) $\alpha$ knock-out mice: evidence for compensatory regulation by PPAR$\delta$,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 26089–26097, 2002.

    View at: Publisher Site | Google Scholar

34. P. J. Brown, T. A. Smith-Oliver, and P. S. Charifson et al., “Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library,” Chemistry and Biology, vol. 4, no. 12, pp. 909–918, 1997.

    View at: Publisher Site | Google Scholar

35. D. C. Dey, R. P. Bronson, J. Dahl, J. P. Carroll, and T. L. Benjamin, “Accelerated development of polyoma tumors and embryonic lethality: different effects of p53 loss on related mouse backgrounds,” Cell Growth & Differentiation, vol. 11, no. 5, pp. 231–237, 2000.

    View at: Google Scholar

36. M. L. Sznaidman, C. D. Haffner, and P. R. Maloney et al., “Novel selective small molecule agonists for peroxisome proliferator-activated receptor $\delta$ (PPAR$\delta$)—synthesis and biological activity,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003.

    View at: Publisher Site | Google Scholar

37. D. B. West, C. N. Boozer, D. L. Moody, and R. L. Atkinson, “Dietary obesity in nine inbred mouse strains,” American Journal of Physiology, vol. 262, no. 6, part 2, pp. R1025–R1032, 1992.

    View at: Google Scholar

38. B. K. Smith, D. B. West, and D. A. York, “Carbohydrate versus fat intake: differing patterns of macronutrient selection in two inbred mouse strains,” The American Journal of Physiology, vol. 272, no. 1, part 2, pp. R357–R362, 1997.

    View at: Google Scholar

39. V. Prpic, P. M. Watson, I. C. Frampton, M. A. Sabol, G. E. Jezek, and T. W. Gettys, “Adaptive changes in adipocyte gene expression differ in AKR/J and SWR/J mice during diet-induced obesity,” Journal of Nutrition, vol. 132, no. 11, pp. 3325–3332, 2002.

    View at: Google Scholar

40. B. Künnecke, P. Verry, A. Bénardeau, and M. von Kienlin, “Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry,” Obesity Research, vol. 12, no. 10, pp. 1604–1615, 2004.

    View at: Google Scholar

41. E. E. Jobst, P. J. Enriori, P. Sinnayah, and M. A. Cowley, “Hypothalamic regulatory pathways and potential obesity treatment targets,” Endocrine, vol. 29, no. 1, pp. 33–48, 2006.

    View at: Publisher Site | Google Scholar

42. P. Escher and W. Wahli, “Peroxisome proliferator-activated receptors: insight into multiple cellular functions,” Mutation Research, vol. 448, no. 2, pp. 121–138, 2000.

    View at: Publisher Site | Google Scholar

43. D. E. Moller and J. P. Berger, “Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation,” International Journal of Obesity, vol. 27, supplement 3, pp. S17–S21, 2003.

    View at: Publisher Site | Google Scholar

44. Y. Iwamoto, K. Kosaka, T. Kuzuya, Y. Akanuma, Y. Shigeta, and T. Kaneko, “Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy,” Diabetes Care, vol. 19, no. 2, pp. 151–156, 1996.

    View at: Publisher Site | Google Scholar

45. M. Narce and J.-P. Poisson, “Novel PPAR$\gamma$-dependent and independent effects for thiazolidinediones,” Current Opinion in Lipidology, vol. 14, no. 6, pp. 651–652, 2003.

    View at: Publisher Site | Google Scholar

46. R. Chakrabarti, R. K. Vikramadithyan, and P. Misra et al., “Ragaglitazar: a novel PPAR$\alpha$ & PPAR$\gamma$ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models,” British Journal of Pharmacology, vol. 140, no. 3, pp. 527–537, 2003.

    View at: Publisher Site | Google Scholar

47. F. Törüner, E. Akbay, and N. Çakir et al., “Effects of PPAR$\gamma$ and PPAR$\alpha$ agonists on serum leptin levels in diet-induced obese rats,” Hormone and Metabolic Research, vol. 36, no. 4, pp. 226–230, 2004.

    View at: Google Scholar

48. M. Rossmeisl, J. S. Rim, R. A. Koza, and L. P. Kozak, “Variation in type 2 diabetes—related traits in mouse strains susceptible to diet-induced obesity,” Diabetes, vol. 52, no. 8, pp. 1958–1966, 2003.

    View at: Publisher Site | Google Scholar

49. L. C. Pickavance, C. L. Brand, K. Wassermann, and J. P. H. Wilding, “The dual PPAR$\alpha /\gamma$ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats,” British Journal of Pharmacology, vol. 144, no. 3, pp. 308–316, 2005.

    View at: Publisher Site | Google Scholar

50. E. H. Koh, M.-S. Kim, and J.-Y. Park et al., “Peroxisome proliferator-activated receptor (PPAR)-$\alpha$ activation prevents diabetes in OLETF rats: comparison with PPAR-$\gamma$ activation,” Diabetes, vol. 52, no. 9, pp. 2331–2337, 2003.

    View at: Publisher Site | Google Scholar

51. M. K. Gee, L. Zhang, S. E. Rankin, J. N. Collins, R. F. Kauffman, and J. D. Wagner, “Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys,” Metabolism, vol. 53, no. 9, pp. 1121–1125, 2004.

    View at: Publisher Site | Google Scholar

52. I. W. Campbell, “The clinical significance of PPAR $\gamma$ agonism,” Current Molecular Medicine, vol. 5, no. 3, pp. 349–363, 2005.

    View at: Publisher Site | Google Scholar

53. C. G. Gegick and M. D. Altheimer, “Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors,” Current Medical Research and Opinion, vol. 20, no. 6, pp. 919–930, 2004.

    View at: Publisher Site | Google Scholar

54. M. W. Stolar and R. J. Chilton, “Type 2 diabetes, cardiovascular risk, and the link to insulin resistance,” Clinical Therapeutics, vol. 25, supplement 2, pp. B4–B31, 2003.

    View at: Publisher Site | Google Scholar

55. H. Duez, J.-C. Fruchart, and B. Staels, “PPARs in inflammation, atherosclerosis and thrombosis,” Journal of Cardiovascular Risk, vol. 8, no. 4, pp. 187–194, 2001.

    View at: Publisher Site | Google Scholar

56. J. M. Way, W. W. Harrington, and K. K. Brown et al., “Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor $\gamma$ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues,” Endocrinology, vol. 142, no. 3, pp. 1269–1277, 2001.

    View at: Publisher Site | Google Scholar

57. S. Hummasti, B. A. Laffitte, and M. A. Watson et al., “Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target,” Journal of Lipid Research, vol. 45, no. 4, pp. 616–625, 2004.

    View at: Publisher Site | Google Scholar

58. G. Martin, K. Schoonjans, B. Staels, and J. Auwerx, “PPAR$\gamma$ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes,” Atherosclerosis, vol. 137, supplement 1, pp. S75–S80, 1998.

    View at: Publisher Site | Google Scholar

59. V. Bocher, I. Pineda-Torra, J.-C. Fruchart, and B. Staels, “PPARS: transcription factors controlling lipid and lipoprotein metabolism,” Annals of the New York Academy of Sciences, vol. 967, pp. 7–18, 2002.

    View at: Google Scholar

60. S. Rocchi and J. Auwerx, “Peroxisome proliferator-activated receptor-$\gamma$: a versatile metabolic regulator,” Annals of Medicine, vol. 31, no. 5, pp. 342–351, 1999.

    View at: Google Scholar

61. F. Picard and J. Auwerx, “PPAR$\gamma$ and glucose homeostasis,” Annual Review of Nutrition, vol. 22, pp. 167–197, 2002.

    View at: Publisher Site | Google Scholar

62. F. Zhang, B. Lavan, and F. M. Gregoire, “Peroxisome proliferator-activated receptors as attractive antiobesity targets,” Drug News and Perspectives, vol. 17, no. 10, pp. 661–669, 2004.

    View at: Publisher Site | Google Scholar

63. A. Fredenrich and P. A. Grimaldi, “PPAR $\delta$: an uncompletely known nuclear receptor,” Diabetes and Metabolism, vol. 31, no. 1, pp. 23–27, 2005.

    View at: Google Scholar

64. S. Luquet, J. Lopez-Soriano, and D. Holst et al., “Roles of peroxisome proliferator-activated receptor $\delta$ (PPAR$\delta$) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome,” Biochimie, vol. 86, no. 11, pp. 833–837, 2004.

    View at: Publisher Site | Google Scholar

65. H. D. Shin, B. L. Park, and L. H. Kim et al., “Genetic polymorphisms in peroxisome proliferator-activated receptor $\delta$ associated with obesity,” Diabetes, vol. 53, no. 3, pp. 847–851, 2004.

    View at: Publisher Site | Google Scholar

66. M. Muurling, R. P. Mensink, H. Pijl, J. A. Romijn, L. M. Havekes, and P. J. Voshol, “Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice,” Metabolism, vol. 52, no. 8, pp. 1078–1083, 2003.

    View at: Publisher Site | Google Scholar

67. M. D. Leibowitz, C. Fiévet, and N. Hennuyer et al., “Activation of PPAR$\delta$ alters lipid metabolism in db/db mice,” FEBS Letters, vol. 473, no. 3, pp. 333–336, 2000.

    View at: Publisher Site | Google Scholar

68. C.-H. Lee, P. Olson, and A. Hevener et al., “PPAR$\delta$ regulates glucose metabolism and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444–3449, 2006.

    View at: Publisher Site | Google Scholar

69. Y. Fukui, S.-I. Masui, S. Osada, K. Umesono, and K. Motojima, “A new thiazolidinedione, NC-2100, which is a weak PPAR-$\gamma$ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice,” Diabetes, vol. 49, no. 5, pp. 759–767, 2000.

    View at: Google Scholar

70. N. L. Bodkin, J. Pill, K. Meyer, and B. C. Hansen, “The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys,” Hormone and Metabolic Research, vol. 35, no. 10, pp. 617–624, 2003.

    View at: Publisher Site | Google Scholar

71. E. H. Koh, M.-S. Kim, and J.-Y. Park et al., “Peroxisome proliferator-activated receptor (PPAR)-$\alpha$ activation prevents diabetes in OLETF rats: comparison with PPAR-$\gamma$ activation,” Diabetes, vol. 52, no. 9, pp. 2331–2337, 2003.

    View at: Publisher Site | Google Scholar

72. P. J. Larsen, P. B. Jensen, and R. V. Sørensen et al., “Differential influences of peroxisome proliferator-activated receptors $\gamma$ and -$\alpha$ on food intake and energy homeostasis,” Diabetes, vol. 52, no. 9, pp. 2249–2259, 2003.

    View at: Publisher Site | Google Scholar

73. J. C. Corton, U. Apte, and S. P. Anderson et al., “Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors,” Journal of Biological Chemistry, vol. 279, no. 44, pp. 46204–46212, 2004.

    View at: Publisher Site | Google Scholar

74. P. Ferré, “The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity,” Diabetes, vol. 53, supplemnet 1, pp. S43–S50, 2004.

    View at: Google Scholar

75. V. Navarro, A. Fernández-Quintela, I. Churruca, and M. P. Portillo, “The body fat-lowering effect conjugated linoleic acid: a comparison between animal and human studies,” Journal of Physiology and Biochemistry, vol. 62, no. 2, pp. 137–147, 2006.

    View at: Google Scholar

76. F. Djouadi, J. M. Brandt, C. J. Weinheimer, T. C. Leone, F. J. Gonzalez, and D. P. Kelly, “The role of the peroxisome proliferator-activated receptor $\alpha$ (PPAR$\alpha$) in the control of cardiac lipid metabolism,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 60, no. 5-6, pp. 339–343, 1999.

    View at: Publisher Site | Google Scholar